Image guided treatment optimalization with cetuximab for patients with metastatic colorectal cancer: IMPACT - CRC
Read time: 1 mins
Last updated:30th Aug 2013
PART I: 1) to demonstrate 89Zr-cetuximab uptake in non-hepatic metastases at standard dose or at cohort wise increased cetuximab doses (dose escalation). 2) to determine the association between 89Zr-cetuximab uptake in non-hepatic metastases and treatment response. PART II To determine the response rate with an optimized dose of cetuximab as has been selected in part 1 in patients without 89Zr-cetuximab tumor uptake at standard dose of cetuximab (dose extension).
|Study start date||2013-08-30|